From developers to esports stars to visionaries, Black excellence exists at every gaming level, so you have no excuse not to ...

Chris is a writer and editor with over 10 years of experience covering games and has a bachelor's degree in History from the University of Central Lancashire. He's mainly focused on guides, but has ...

GameSpot may receive revenue from affiliate and advertising partnerships for sharing this content and from purchases through links. Baldur’s Gate 3 and Divinity developer Larian has confirmed that it ...

Uber Technologies Inc. has set usage caps on some artificial intelligence-powered tools used by its staff, a move meant to manage costs after the company blew through its AI budget earlier this year.

OpenAI announced it will acquire Ona, a startup that provides cloud environments for AI agents. Ona's technology will allow OpenAI's coding assistant, Codex, to take on longer-running tasks, OpenAI ...

Evan is a Communications student based in Edmonton, Alberta. Formerly a sports writer, he was drawn to Game Rant by his longtime passion for video games. An avid gamer since the age of 13, Evan has ...

Two of the Spurs’ most visible fans will not be in their seats for Game 2 of the NBA Finals after an incident at a previous playoff contest left them so shaken that it “has greatly shifted” their ...

Everyone from kids to grandmas is vibe coding. Here's an easy guide on how to start.

Anthropic is releasing Claude Fable 5 for general users. Fable 5 uses Mythos-class power with safety controls. Pricing is about twice that of Claude Opus 4.8. Anthropic has announced a defanged ...

Uber is setting limits on how much employees can spend on artificial intelligence agents after its workers blew through their yearly AI coding budget in just four months. Each employee at the ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Every time I see someone opening ChatGPT on the subway or at the grocery store, I feel a tinge of ...

Johnson & Johnson (JNJ) reported new clinical trial results showing that its experimental subcutaneous formulation of amivantamab produced durable responses in patients with advanced head and neck ...